RxDoctor Payments Data

Daniela Ciltea, MD

Endocrinology, Diabetes & Metabolism · Akron, OHNPI 1518186360

Payments from drug & device makers

$14,506in general payments, 2019–2025

Across 72 payments — averaging $201.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$13K
  • Novo Nordisk$400
  • Amgen$207
  • Bayer$122
  • Merck$110
  • Amarin Pharma, Inc.$64
  • plus $487 from 17 others

What the payments were for

  • Speaking & faculty fees$12,82588%
  • Food & beverage$1,66912%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,506 in reported general payments places this provider in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$60,077
Medicare patients
272
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide228$364,495
JardianceEmpagliflozin187$281,971
Teriparatide45$212,172
MounjaroTirzepatide121$173,600
TrulicityDulaglutide123$172,592
RybelsusSemaglutide30$56,002
TradjentaLinagliptin53$54,442
CreonLipase/Protease/Amylase15$50,559
Tresiba Flextouch U-200Insulin Degludec49$48,775
FarxigaDapagliflozin Propanediol40$47,843
JanuviaSitagliptin Phosphate42$46,067
Tresiba Flextouch U-100Insulin Degludec61$36,354
Fiasp FlextouchInsulin Aspart (Niacinamide)41$34,799
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$29,770
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$25,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$400$426,363279 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$13,116$357,324302 claims
Boehringer IngelheimJardiance, Tradjenta$35$336,413240 claims
AbbVieCreon, Synthroid$61$64,213207 claims
AstraZenecaFarxiga$45$47,84340 claims
MerckJanuvia$110$46,06742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →